Full Text View
Tabular View
No Study Results Posted
Related Studies
Effects of Growth Hormone (GH) Treatment on Eating Regulation
This study is not yet open for participant recruitment.
Verified by Rabin Medical Center, October 2007
First Received: November 21, 2007   Last Updated: December 9, 2007   History of Changes
Sponsor: Rabin Medical Center
Information provided by: Rabin Medical Center
ClinicalTrials.gov Identifier: NCT00562705
  Purpose

This is a two arm, randomized, prospective, intervention study in order to determine the effects of growth hormone treatment on eating regulation and to compare between the growth responses with or without nutritional intervention in short stature children.

The study will include 30 short stature children that are about to initiate growth hormone treatment and will last for one year. After 4 months of treatment, children will be randomized into two groups:

  1. Control group that will continue with growth hormone treatment without any other intervention.
  2. Study group that will be a given a nutritional intervention in addition to growth hormone treatment.

At screening visit and during the study the following parameters will be evaluated: height, weight, growth markers in the blood and urine, child eating behavior questionnaire, blood tests, hormonal tests and resting energy expenditure measurements.


Condition Intervention
Short Stature
Behavioral: growth hormone- Genotropin or NorditropinSimplex and nutritional intervention
Behavioral: growth hormone-Genotropin or NorditropinSimplex or Biotropin

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title: Effects of Growth Hormone Treatment on Eating Regulation and Comparison Between the Growth Responses With or Without Nutritional Intervention in Short Stature Children

Resource links provided by NLM:


Further study details as provided by Rabin Medical Center:

Primary Outcome Measures:
  • height and weight [ Time Frame: every visit until the end of study ] [ Designated as safety issue: No ]
  • Growth markers [ Time Frame: At screening visit, baseline and at the end of the visit ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety laboratory parameters [ Time Frame: at screening, baseline and at the end of the study ] [ Designated as safety issue: Yes ]
  • food diary [ Time Frame: every visit until the end of the study ] [ Designated as safety issue: No ]
  • Resting energy expenditure measurements [ Time Frame: Every visit other than visit number 4 ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: January 2008
Estimated Study Completion Date: January 2010
Arms Assigned Interventions
1: Experimental
Growth hormone and nutritional intervention
Behavioral: growth hormone- Genotropin or NorditropinSimplex and nutritional intervention
A combined treatment of growth hormone (Genotropin or NorditropinSimplex or Biotropin) and nutritional intervention
2: Active Comparator
growth hormone
Behavioral: growth hormone-Genotropin or NorditropinSimplex or Biotropin
Growth hormone treatment (Genotropin, or NorditropinSimplex or Biotropin).

Detailed Description:

This is a two arm, randomized, prospective, intervention study in order to determine the effects of growth hormone treatment on eating regulation and to compare between the growth responses with or without nutritional intervention in short stature children.

Background:

In the last three decades children with different kinds of short stature pathologies were treated with growth hormone. Most of the attention in growth hormone studies is focused on the effect of the treatment on growth. Today there are very few studies that are focused on the effect of growth hormone on eating regulations and the connection between eating regulations and growth improvement in growth hormone treatment.

Objectives:

  1. To evaluate the effect of short term growth hormone treatment on the following parameters:

    1. Appetite, food preference, amount of food and ingredients.
    2. Changes in food regulations.
    3. Changes in body composition.
    4. Changes in resting energy expenditure.
    5. Changes in hormones that are associated with appetite and with energy balance: IGF-1,IGFBP1&3 and Ghrelin.
    6. Changes in metabolic and nutritional measurements: glucose, insulin, lipid profile, total proteins, albumin, liver functions, alkaline-phosphatase, hemoglobin, transferrin, iron, B12, folic acid.
  2. To evaluate the effect of nutritional support on growth rate in one year growth hormone treatment.
  3. To evaluate changes in growth markers in the serum and urine during growth hormone treatment.

Methods:

The study will include 30 short stature children that are about to initiate growth hormone treatment and will last for one year. After 4 months of treatment children will be randomized into two groups:

  1. Control group that will continue with growth hormone treatment without any other intervention.
  2. Study group that will be given a nutritional intervention In addition to growth hormone treatment.

The nutritional intervention will include nutritional consultation and applying a personal dietetic menu. At screening visit and during the study the following parameters will be evaluated: height, weight, growth markers in the blood and urine, food diary, child eating behavior questionnaire, resting energy expenditure measurements, blood tests, hormonal tests and fasting and post-prandial levels of leptin, ghrelin, GLP-1, insulin and glucose.

  Eligibility

Ages Eligible for Study:   2 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Height of at least 2.0 standard deviations below the mean height for chronological age and sex according to the 2000 standards from the Centers for Disease Control and Prevention (CDC).
  2. Children that have one of the following short stature pathologies:

    1. IGHD or MPHD
    2. ISS
    3. SGA
  3. Proper function of thyroid gland, kidney and liver
  4. Prior to initiating growth hormone treatment

Exclusion Criteria:

  1. Chronic diseases
  2. Diseases in the digestive system.
  3. Neurological diseases.
  4. Malignant diseases in the past or in the present. Treated with chemotherapy or radiation.
  5. Genetic syndromes
  6. Bone diseases
  7. Taking chronic medicine, SSRI type, that effect the appetite and the growth hormone signal transduction.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00562705

Contacts
Contact: Moshe Phillip, Prof. 03-9253778 mosheph@clalit.org.il

Locations
Israel
Schneider Children's Medical Center
Petach-Tikva, Israel
Sponsors and Collaborators
Rabin Medical Center
Investigators
Principal Investigator: Moshe Phillip, Professor Schneider Children Medical Center
  More Information

No publications provided

Study ID Numbers: rmc004623ctil
Study First Received: November 21, 2007
Last Updated: December 9, 2007
ClinicalTrials.gov Identifier: NCT00562705     History of Changes
Health Authority: Israel: Ministry of Health

Keywords provided by Rabin Medical Center:
growth hormone
eating regulation
nutritional intervention
short stature
ISS
SGA
IGHD
MPHD

Additional relevant MeSH terms:
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Hormones
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 08, 2010